Tissue-Engineered Human Bioartificial Muscles Expressing a Foreign Recombinant Protein for Gene Therapy
- 1 March 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 10 (4) , 565-577
- https://doi.org/10.1089/10430349950018643
Abstract
Murine skeletal muscle cells transduced with foreign genes and tissue engineered in vitro into bioartificial muscles (BAMs) are capable of long-term delivery of soluble growth factors when implanted into syngeneic mice (Vandenburgh et al ., 1996b). With the goal of developing a therapeutic cell-based protein delivery system for humans, similar genetic tissue-engineering techniques were designed for human skeletal muscle stem cells. Stem cell myoblasts were isolated, cloned, and expanded in vitro from biopsied healthy adult (mean age, 42 +/- 2 years), and elderly congestive heart failure patient (mean age, 76 +/- 1 years) skeletal muscle. Total cell yield varied widely between biopsies (50 to 672 per 100 mg of tissue, N = 10), but was not significantly different between the two patient groups. Percent myoblasts per biopsy (73 +/- 6%), number of myoblast doublings prior to senescence in vitro (37 +/- 2), and myoblast doubling time (27 +/- 1 hr) were also not significantly different between the two patient groups. Fusion kinetics of the myoblasts were similar for the two groups after 20-22 doublings (74 +/- 2% myoblast fusion) when the biopsy samples had been expanded to 1 to 2 billion muscle cells, a number acceptable for human gene therapy use. The myoblasts from the two groups could be equally transduced ex vivo with replication-deficient retroviral expression vectors to secrete 0.5 to 2 mu g of a foreign protein (recombinant human growth hormone, rhGH)/106 cells/day, and tissue engineered into human BAMs containing parallel arrays of differentiated, postmitotic myofibers. This work suggests that autologous human skeletal myoblasts from a potential patient population can be isolated, genetically modified to secrete foreign proteins, and tissue engineered into implantable living protein secretory devices for therapeutic use.Keywords
This publication has 47 references indexed in Scilit:
- Attenuation of Skeletal Muscle Wasting with Recombinant Human Growth Hormone Secreted from a Tissue-Engineered Bioartificial MuscleHuman Gene Therapy, 1998
- A Novel Gene Delivery System Using Urothelial Tissue Engineered Neo-OrgansJournal of Urology, 1997
- Tissue-Engineered Skeletal Muscle Organoids for Reversible Gene TherapyHuman Gene Therapy, 1996
- Prolonged Expression of Therapeutic Levels of Human Granulocyte Colony-Stimulating Factor in Rats Following Gene Transfer to Skeletal MuscleHuman Gene Therapy, 1996
- Long-Term Expression of the Biologically Active Growth Hormone in Genetically Modified Fibroblasts after Implantation into a Hypophysectomized RatHuman Gene Therapy, 1995
- Tissue EngineeringScience, 1993
- Differentiation of human skeletal muscle cells in culture: maturation as indicated by titin and desmin striationCell and tissue research, 1992
- Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: Implications for cell and gene therapySomatic Cell and Molecular Genetics, 1990
- Towards An Artificial Cornea: Surface Modifications of Optically Clear, Oxygen Permeable Soft Contact Lens Materials by Ammonia Plasma Modification Technique for the Enhanced Attachment and Growth of Corneal Epithelial CellsBiomaterials, Artificial Cells and Artificial Organs, 1990
- Fibroblasts promote the formation of a continuous basal lamina during myogenesis in vitro.The Journal of cell biology, 1986